We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Airway Therapeutics, Inc. (Airway) announced dosing of the first patient on August 17, 2021 in the AT-100 (rhSP-D) Phase 1b trial in mechanically-ventilated COVID-19 patients.